Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that it is initiating a Phase 2b study of narmafotinib in pancreatic cancer exploring a new dosing regimen.

The death toll in this year’s summer initiation season has risen to 41, with authorities urging parents to ensure their sons’ safety Minister Velenkosini Hlabisa and Deputy Minister Xolile ...

A family spent the weekend negotiating with traditional leaders for the release of a young boy from an initiation school. The 17-year-old fled his home near Kwamhlanga in Mpumalanga at roughly 5pm on ...

Glucotrack, Inc. has announced progress towards the clinical implementation of its fully implantable continuous blood glucose monitor (CBGM) system, with plans to start implanting the first patients ...

Catholic Communities in New Zealand and Australia join forces to host a July virtual conference looking at rebuilding after the pandemic. Alive in the Spirit: That’s the title of a virtual conference ...

Copyright: © 2025 The Authors. Published by Elsevier Ltd. We obtained data from the Illicit Drug Reporting System (IDRS) and the Australian Needle Syringe Program ...

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and ...

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for ...